55 results
8-K
EX-99.1
GRI
GRI Bio Inc
1 Apr 24
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
9:13am
. Maher et al., Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 22, 197 (2021)
Research and development expenses were $3.2 … million and $0.2 million for the years ended December 31, 2023 and 2022, respectively. The $3.0 million increase in research and development expenses
424B3
GRI
GRI Bio Inc
28 Mar 24
Prospectus supplement
4:45pm
not obtain additional financing.
Risks Related to Research and Development and the Pharmaceutical Industry
Our business is highly dependent on the success … be substantially harmed.
Because we rely on third-party manufacturing and supply vendors, our supply of research and development, preclinical and clinical
424B3
GRI
GRI Bio Inc
28 Mar 24
Prospectus supplement
4:42pm
not obtain additional financing.
Risks Related to Research and Development and the Pharmaceutical Industry
Our business is highly dependent on the success … be substantially harmed.
Because we rely on third-party manufacturing and supply vendors, our supply of research and development, preclinical and clinical
424B3
tlwnwnpmlcie4aw mn
2 Feb 24
Prospectus supplement
4:25pm
8-K
EX-10.1
pwuehz
2 Feb 24
GRI Bio Announces Pricing of $5.5 Million Public Offering
4:23pm
424B4
lecuud4xi
2 Feb 24
Prospectus supplement with pricing info
4:21pm
424B3
3ldofy emvnwkzsh5
15 Dec 23
Prospectus supplement
5:02pm
8-K
EX-99.1
buk0wp5u9fw a26kx
15 Nov 23
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis ("IPF") on track to start before year end 2023; Interim data expected H1 2024
8:07am
8-K
EX-99.1
l3fhaex0 dv
14 Aug 23
On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF before year end 2023
8:06am
8-K/A
EX-99.1
8u0k1e50 gjme3czwusf
6 Jul 23
Financial Statements and Exhibits
4:28pm